Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Glynne

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
British Journal of Cancer|May 14, 2009
Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosisS Rasheed, A L Harris, P P Tekkis, et al.
Pathology, Research and Practice|November 15, 2008
Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancerS Rasheed, A L Harris, P P Tekkis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trialR Glynne-Jones, L Kadalayil, H M Meadows, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|November 26, 2013
The English national low rectal cancer development programme: key messages and future perspectivesB J Moran, T Holm, G Brannagan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancerD Cunningham, B Sirohi, A Pluzanska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2014
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013D Papamichael, R A Audisio, B Glimelius, et al.
Heliyon|September 28, 2018
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)R Glynne-Jones, M R Hall, A Lopes, et al.
International Journal of Colorectal Disease|May 3, 2005
Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?R Hughes, R Glynne-Jones, J Grainger, et al.
BMC Cancer|October 24, 2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectumR Glynne-Jones, N Hava, V Goh, et al.
The British Journal of Surgery|July 9, 2021
Prevalence of nodal involvement in rectal cancer after chemoradiotherapyH E Haak, G L Beets, K Peeters, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
British Journal of Cancer|May 14, 2009
Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosisS Rasheed, A L Harris, P P Tekkis, et al.
Pathology, Research and Practice|November 15, 2008
Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancerS Rasheed, A L Harris, P P Tekkis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trialR Glynne-Jones, L Kadalayil, H M Meadows, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|November 26, 2013
The English national low rectal cancer development programme: key messages and future perspectivesB J Moran, T Holm, G Brannagan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancerD Cunningham, B Sirohi, A Pluzanska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2014
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013D Papamichael, R A Audisio, B Glimelius, et al.
Heliyon|September 28, 2018
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)R Glynne-Jones, M R Hall, A Lopes, et al.
International Journal of Colorectal Disease|May 3, 2005
Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?R Hughes, R Glynne-Jones, J Grainger, et al.
BMC Cancer|October 24, 2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectumR Glynne-Jones, N Hava, V Goh, et al.
The British Journal of Surgery|July 9, 2021
Prevalence of nodal involvement in rectal cancer after chemoradiotherapyH E Haak, G L Beets, K Peeters, et al.
Pageof 9